

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K variant, by vaccine-elicited sera

Nature Medicine

27, 620-621

DOI: [10.1038/s41591-021-01270-4](https://doi.org/10.1038/s41591-021-01270-4)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | The Genetic Variant of SARS-CoV-2: Would it matter for Controlling the Devastating Pandemic?. International Journal of Biological Sciences, 2021, 17, 1476-1485. | 6.4 | 23 |
| 2 | AutoVEM2: A flexible automated tool to analyze candidate key mutations and epidemic trends for virus. Computational and Structural Biotechnology Journal, 2021, 19, 5029-5038. | 4.1 | 4 |
| 3 | Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. Emerging Microbes and Infections, 2021, 10, 1931-1946. | 6.5 | 11 |
| 4 | An overview of current COVID-19 vaccine platforms. Computational and Structural Biotechnology Journal, 2021, 19, 2508-2517. | 4.1 | 99 |
| 7 | Tri-primer-enhanced strand exchange amplification combined with rapid lateral flow fluorescence immunoassay to detect SARS-CoV-2. Analyst, The, 2021, 146, 6650-6664. | 3.5 | 4 |
| 8 | Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant. Emerging Microbes and Infections, 2021, 10, 1284-1292. | 6.5 | 25 |
| 9 | Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2. Emerging Microbes and Infections, 2021, 10, 1499-1502. | 6.5 | 9 |
| 10 | A rapid screening assay for L452R and T478K spike mutations in SARS-CoV-2 Delta variant using high-resolution melting analysis. Journal of Toxicological Sciences, 2021, 46, 471-476. | 1.5 | 27 |
| 12 | Making sense of spike D614G in SARS-CoV-2 transmission. Science China Life Sciences, 2021, 64, 1062-1067. | 4.9 | 8 |
| 29 | Vaccination hesitancy and the "myth" on mRNA-based vaccines in Italy in the COVID-19 era: Does urgency meet major safety criteria?. Journal of Medical Virology, 2021, 93, 4049-4053. | 5.0 | 23 |
| 31 | Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature, 2021, 593, 142-146. | 27.8 | 574 |
| 36 | Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results. Frontiers in Immunology, 2021, 12, 657711. | 4.8 | 50 |
| 38 | Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications. Viruses, 2021, 13, 439. | 3.3 | 107 |
| 40 | Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nature Medicine, 2021, 27, 717-726. | 30.7 | 838 |
| 41 | The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. Npj Vaccines, 2021, 6, 44. | 6.0 | 36 |
| 42 | SARS-CoV-2 Episode 2? A sequel nobody wants to see. Clinical Infectious Diseases, 2021, , . | 5.8 | 0 |
| 44 | Immunity to SARS-CoV-2: Lessons Learned. Frontiers in Immunology, 2021, 12, 654165. | 4.8 | 33 |
| 47 | Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective. Viruses, 2021, 13, 418. | 3.3 | 51 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 49 | Perception of COVID-19 Vaccination Amongst Physicians in Colombia. <i>Vaccines</i> , 2021, 9, 287. | 4.4 | 30 |
| 51 | Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. <i>Reviews in Medical Virology</i> , 2021, 31, e2231. | 8.3 | 128 |
| 55 | Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. <i>Vaccines</i> , 2021, 9, 243. | 4.4 | 217 |
| 61 | Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. <i>Nature Medicine</i> , 2021, 27, 917-924. | 30.7 | 617 |
| 62 | The effect of spike mutations on SARS-CoV-2 neutralization. <i>Cell Reports</i> , 2021, 34, 108890. | 6.4 | 200 |
| 64 | BNT162b2 mRNA COVID-19 Vaccine: First Approval. <i>Drugs</i> , 2021, 81, 495-501. | 10.9 | 232 |
| 65 | Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. <i>Nature</i> , 2021, 593, 130-135. | 27.8 | 1,904 |
| 68 | SARS-CoV-2 variants: a new challenge to convalescent serum and mRNA vaccine neutralization efficiency. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 151. | 17.1 | 17 |
| 70 | Research, Development and Application of COVID-19 Vaccines: Progress, Challenges, and Prospects. <i>Journal of Exploratory Research in Pharmacology</i> , 2021, 000, 000-000. | 0.4 | 0 |
| 71 | The variant gambit: COVID-19's next move. <i>Cell Host and Microbe</i> , 2021, 29, 508-515. | 11.0 | 305 |
| 73 | Emergence and Spread of SARS-CoV-2 Lineages B.1.1.7 and P.1 in Italy. <i>Viruses</i> , 2021, 13, 794. | 3.3 | 32 |
| 74 | Paediatric research in the times of COVID-19. <i>Pediatric Research</i> , 2021, 90, 267-271. | 2.3 | 8 |
| 75 | Obesity and its impact on COVID-19. <i>Journal of Molecular Medicine</i> , 2021, 99, 899-915. | 3.9 | 41 |
| 76 | Surveillance of SARS-CoV-2 in Frankfurt am Main from October to December 2020 Reveals High Viral Diversity Including Spike Mutation N501Y in B.1.1.70 and B.1.1.7. <i>Microorganisms</i> , 2021, 9, 748. | 3.6 | 14 |
| 77 | Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes. <i>Virology Journal</i> , 2021, 18, 87. | 3.4 | 27 |
| 79 | mRNA-Based Vaccines. <i>Vaccines</i> , 2021, 9, 390. | 4.4 | 67 |
| 81 | Adapt or perish: SARS-CoV-2 antibody escape variants defined by deletions in the Spike N-terminal Domain. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 164. | 17.1 | 12 |
| 82 | Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape. <i>ACS Nano</i> , 2021, 15, 5793-5818. | 14.6 | 32 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 83 | Inferring the Association between the Risk of COVID-19 Case Fatality and N501Y Substitution in SARS-CoV-2. <i>Viruses</i> , 2021, 13, 638. | 3.3 | 21 |
| 84 | Immunogenicity and efficacy of one and two doses of Ad26.COVS.S COVID vaccine in adult and aged NHP. <i>Journal of Experimental Medicine</i> , 2021, 218, . | 8.5 | 55 |
| 85 | Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. <i>Expert Review of Vaccines</i> , 2021, 20, 365-373. | 4.4 | 139 |
| 86 | SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. <i>Cell</i> , 2021, 184, 2384-2393.e12. | 28.9 | 848 |
| 89 | A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence. <i>Cell</i> , 2021, 184, 2229-2238.e13. | 28.9 | 51 |
| 90 | The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines?. <i>Expert Review of Vaccines</i> , 2021, 20, 635-638. | 4.4 | 66 |
| 91 | Inhibitory effect of anti-HIV compounds extracted from Indian medicinal plants to retard the replication and transcription process of SARS-CoV-2: an insight from molecular docking and MD-simulation studies. <i>Network Modeling Analysis in Health Informatics and Bioinformatics</i> , 2021, 10, 32. | 2.1 | 16 |
| 92 | SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. <i>Cell Host and Microbe</i> , 2021, 29, 522-528.e2. | 11.0 | 173 |
| 95 | Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations. <i>Biochemistry</i> , 2021, 60, 1459-1484. | 2.5 | 62 |
| 96 | Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. <i>Cell Host and Microbe</i> , 2021, 29, 516-521.e3. | 11.0 | 199 |
| 98 | Implications of the Novel Mutations in the SARS-CoV-2 Genome for Transmission, Disease Severity, and the Vaccine Development. <i>Frontiers in Medicine</i> , 2021, 8, 636532. | 2.6 | 56 |
| 100 | BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2895-2998. | 5.7 | 29 |
| 102 | Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 818-823. | 12.6 | 309 |
| 108 | Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers. <i>Clinical Infectious Diseases</i> , 2022, 74, 707-710. | 5.8 | 10 |
| 109 | Glimpses into evolutionary trajectories of SARS-CoV-2: emerging variants and potential immune evasion routes. <i>Future Microbiology</i> , 2021, 16, 455-459. | 2.0 | 3 |
| 110 | Prediction and Evolution of the Molecular Fitness of SARS-CoV-2 Variants: Introducing SpikePro. <i>Viruses</i> , 2021, 13, 935. | 3.3 | 22 |
| 111 | SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. <i>Science Immunology</i> , 2021, 6, . | 11.9 | 455 |
| 112 | RT-qPCR Assays for Rapid Detection of the N501Y, 69-70del, K417N, and E484K SARS-CoV-2 Mutations: A Screening Strategy to Identify Variants With Clinical Impact. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 672562. | 3.9 | 60 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 113 | SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. Advanced Drug Delivery Reviews, 2021, 172, 314-338. | 13.7 | 75 |
| 114 | The Spike of Concern—The Novel Variants of SARS-CoV-2. Viruses, 2021, 13, 1002. | 3.3 | 92 |
| 115 | Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population. International Reviews of Immunology, 2021, , 1-16. | 3.3 | 6 |
| 116 | Advances of nanomaterials-based strategies for fighting against COVID-19. View, 2021, 2, 20200180. | 5.3 | 16 |
| 117 | Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K. Journal of Medical Virology, 2021, 93, 5638-5643. | 5.0 | 129 |
| 118 | SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies. Nature Medicine, 2021, 27, 759-761. | 30.7 | 65 |
| 119 | SARS-CoV-2 worldwide replication drives rapid rise and selection of mutations across the viral genome: a time-course study — potential challenge for vaccines and therapies. EMBO Molecular Medicine, 2021, 13, e14062. | 6.9 | 28 |
| 122 | Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 72-82. | 5.7 | 11 |
| 124 | Sensitive Immunodetection of Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern 501Y.V2 and 501Y.V1. Journal of Infectious Diseases, 2021, 224, 616-619. | 4.0 | 3 |
| 126 | Response to mutation and variants of the SARS-CoV-2 gene. Universa Medicina, 2021, 40, 77-78. | 0.2 | 3 |
| 127 | On the road to ending the COVID-19 pandemic: Are we there yet?. Virology, 2021, 557, 70-85. | 2.4 | 38 |
| 128 | COVID-19: vaccination problems. Environmental Microbiology, 2021, 23, 2878-2890. | 3.8 | 46 |
| 129 | COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy. Human Genomics, 2021, 15, 27. | 2.9 | 39 |
| 130 | BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature, 2021, 595, 572-577. | 27.8 | 583 |
| 131 | Use of Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDs. Diagnostics, 2021, 11, 1190. | 2.6 | 10 |
| 133 | Observational study on healthcare workers protection in the angiographic suite during the SARS-CoV-2 pandemic: before and during vax era. Journal of Public Health Research, 2021, 10, . | 1.2 | 1 |
| 134 | Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization. AAPS PharmSciTech, 2021, 22, 172. | 3.3 | 24 |
| 135 | Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis. Molecules and Cells, 2021, 44, 392-400. | 2.6 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 136 | Rapid Increase of SARS-CoV-2 Variant B.1.1.7 Detected in Sewage Samples from England between October 2020 and January 2021. <i>MSystems</i> , 2021, 6, e0035321. | 3.8 | 46 |
| 137 | Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans. <i>Vaccines</i> , 2021, 9, 588. | 4.4 | 12 |
| 138 | Application of an integrated computational antibody engineering platform to design SARS-CoV-2 neutralizers. <i>Antibody Therapeutics</i> , 2021, 4, 109-122. | 1.9 | 8 |
| 140 | SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389. | 3.6 | 4 |
| 141 | SARS-CoV-2 variants, spike mutations and immune escape. <i>Nature Reviews Microbiology</i> , 2021, 19, 409-424. | 28.6 | 2,650 |
| 142 | Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 2187-2201. | 27.0 | 1,954 |
| 144 | Rapid Detection of SARS-CoV-2 Variants of Concern, Including B.1.1.28/P.1, British Columbia, Canada. <i>Emerging Infectious Diseases</i> , 2021, 27, 1673-1676. | 4.3 | 38 |
| 145 | Adjusting extracellular pH to prevent entry of SARS-CoV-2 into human cells. <i>Genome</i> , 2021, 64, 595-598. | 2.0 | 7 |
| 146 | An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immuno-response with single dose. <i>Vaccine</i> , 2021, 39, 3745-3755. | 3.8 | 9 |
| 147 | SARS-CoV-2 Brazil variants in Latin America: More serious research urgently needed on public health and vaccine protection. <i>Annals of Medicine and Surgery</i> , 2021, 66, 102428. | 1.1 | 18 |
| 149 | Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. <i>Science</i> , 2021, 373, . | 12.6 | 318 |
| 150 | Detection of R.1 lineage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan. <i>PLoS Pathogens</i> , 2021, 17, e1009619. | 4.7 | 40 |
| 151 | In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021, 596, 103-108. | 27.8 | 222 |
| 152 | CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 4048. | 12.8 | 45 |
| 153 | SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. <i>Viruses</i> , 2021, 13, 1211. | 3.3 | 35 |
| 155 | Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes. <i>MBio</i> , 2021, 12, e0069621. | 4.1 | 61 |
| 156 | Allosteric Cross-Talk among Spike's Receptor-Binding Domain Mutations of the SARS-CoV-2 South African Variant Triggers an Effective Hijacking of Human Cell Receptor. <i>Journal of Physical Chemistry Letters</i> , 2021, 12, 5987-5993. | 4.6 | 33 |
| 158 | BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. <i>Nature</i> , 2021, 596, 273-275. | 27.8 | 318 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 159 | SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2. <i>Cells</i> , 2021, 10, 1434. | 4.1 | 60 |
| 160 | SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions. <i>Scientific Reports</i> , 2021, 11, 11998. | 3.3 | 17 |
| 161 | SARS-CoV-2 spillover transmission due to recombination event. <i>Gene Reports</i> , 2021, 23, 101045. | 0.8 | 11 |
| 162 | The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. <i>Frontiers in Immunology</i> , 2021, 12, 687869. | 4.8 | 23 |
| 165 | Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. <i>Nature Medicine</i> , 2021, 27, 1379-1384. | 30.7 | 296 |
| 168 | Adaptation of the endemic coronaviruses HCoV-OC43 and HCoV-229E to the human host. <i>Virus Evolution</i> , 2021, 7, veab061. | 4.9 | 12 |
| 169 | Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 226. | 17.1 | 103 |
| 170 | Fncas9-based CRISPR diagnostic for rapid and accurate detection of major SARS-CoV-2 variants on a paper strip. <i>ELife</i> , 2021, 10, . | 6.0 | 53 |
| 171 | Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination. <i>Clinical Infectious Diseases</i> , 2021, 73, 2000-2008. | 5.8 | 30 |
| 172 | Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. <i>Cell</i> , 2021, 184, 3426-3437.e8. | 28.9 | 424 |
| 174 | COVID-19: 1/4D,Ñ,,Ñ< Ð, Ñ€ÐµÐ°Ð»Ñ€Ð1/2Ð3/4ÑÑ,Ñ€€. <i>Biochemistry</i> , 2021, 86, 964-984. | 0.0 | 0 |
| 175 | SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. <i>Frontiers in Immunology</i> , 2021, 12, 701501. | 4.8 | 157 |
| 176 | SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. <i>Science</i> , 2021, 373, 648-654. | 12.6 | 385 |
| 179 | Molecular definition of severe acute respiratory syndrome coronavirus 2 receptorâ€binding domain mutations: Receptor affinity versus neutralization of receptor interaction. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 143-149. | 5.7 | 26 |
| 180 | Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC:) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 | 4.4 | 94 |
| 181 | Potency of BNT162b2 and mRNAâ€1273 vaccineâ€induced neutralizing antibodies against severe acute respiratory syndromeâ€CoVâ€2 variants of concern: A systematic review of in vitro studies. <i>Reviews in Medical Virology</i> , 2022, 32, e2277. | 8.3 | 57 |
| 182 | SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. <i>Cell Reports</i> , 2021, 36, 109415. | 6.4 | 206 |
| 183 | Multiplex SARS-CoV-2 Genotyping Reverse Transcriptase PCR for Population-Level Variant Screening and Epidemiologic Surveillance. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0085921. | 3.9 | 82 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 184 | SARS-CoV-2 Mutations and their Viral Variants. Cytokine and Growth Factor Reviews, 2022, 63, 10-22. | 7.2 | 113 |
| 185 | The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Brazilian Journal of Infectious Diseases, 2021, 25, 101606. | 0.6 | 94 |
| 187 | Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection. PLoS Pathogens, 2021, 17, e1009715. | 4.7 | 24 |
| 188 | Navigating post-vaccine COVID-19 futures in the health and economic context. Lancet Infectious Diseases, The, 2021, 21, 893-894. | 9.1 | 3 |
| 190 | Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses. Molecular Biology, 2021, 55, 538-547. | 1.3 | 2 |
| 192 | COVID-19: Myths and Reality. Biochemistry (Moscow), 2021, 86, 800-817. | 1.5 | 10 |
| 195 | COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. Biomolecules, 2021, 11, 993. | 4.0 | 136 |
| 196 | An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status. Clinical Infectious Diseases, 2022, 74, 1208-1219. | 5.8 | 64 |
| 201 | Clinical and virological course of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center cohort study. Virology Journal, 2021, 18, 147. | 3.4 | 2 |
| 203 | Original Hosts, Clinical Features, Transmission Routes, and Vaccine Development for Coronavirus Disease (COVID-19). Frontiers in Medicine, 2021, 8, 702066. | 2.6 | 14 |
| 204 | Possible Targets of Pan-Coronavirus Antiviral Strategies for Emerging or Re-Emerging Coronaviruses. Microorganisms, 2021, 9, 1479. | 3.6 | 10 |
| 205 | Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. Cell Host and Microbe, 2021, 29, 1151-1161.e5. | 11.0 | 36 |
| 208 | Rapid evolution of the COVID-19 pandemic calls for a unified public health response. BioScience Trends, 2021, 15, 196-200. | 3.4 | 5 |
| 209 | Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor. Cell and Bioscience, 2021, 11, 168. | 4.8 | 69 |
| 210 | BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects. Life, 2021, 11, 896. | 2.4 | 2 |
| 211 | Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. Vaccines, 2021, 9, 910. | 4.4 | 50 |
| 212 | B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies. MBio, 2021, 12, e0138621. | 4.1 | 52 |
| 214 | Assessment of the potentially decreased neutralizing activities of intravenous immunoglobulin against future coronavirus variants. Transfusion, 2021, 61, 2514-2515. | 1.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 215 | Probing the Increased Virulence of Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617 (Indian) Tj ETQq0 0 0 rgBT /Overlock 10 T | 0.5 | 3 |
| 216 | Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. JCI Insight, 2021, 6, . | 5.0 | 33 |
| 217 | One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages. Infection, Genetics and Evolution, 2021, 92, 104869. | 2.3 | 49 |
| 218 | Computationally Designed ACE2 Decoy Receptor Binds SARS-CoV-2 Spike (S) Protein with Tight Nanomolar Affinity. Journal of Chemical Information and Modeling, 2021, 61, 4656-4669. | 5.4 | 24 |
| 219 | SARS-CoV-2 vaccines â€” the biggest medical research project of the 21st century. Current Opinion in Virology, 2021, 49, 52-57. | 5.4 | 12 |
| 220 | The impact of high-resolution structural data on stemming the COVID-19 pandemic. Current Opinion in Virology, 2021, 49, 127-138. | 5.4 | 2 |
| 221 | Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. Signal Transduction and Targeted Therapy, 2021, 6, 317. | 17.1 | 68 |
| 222 | Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nature Reviews Immunology, 2021, 21, 626-636. | 22.7 | 777 |
| 223 | An Analysis Based on Molecular Docking and Molecular Dynamics Simulation Study of Bromelain as Anti-SARS-CoV-2 Variants. Frontiers in Pharmacology, 2021, 12, 717757. | 3.5 | 28 |
| 224 | Evolutionary trajectory of SARS-CoV-2 and emerging variants. Virology Journal, 2021, 18, 166. | 3.4 | 105 |
| 225 | SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants. Viruses, 2021, 13, 1687. | 3.3 | 57 |
| 226 | The rapid adaptation of SARS-CoV-2â€”rise of the variants: transmission and resistance. Journal of Microbiology, 2021, 59, 807-818. | 2.8 | 18 |
| 228 | An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms. Turkish Journal of Biology, 2021, 45, 342-357. | 0.8 | 3 |
| 229 | Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. Biochemical and Biophysical Research Communications, 2021, 566, 135-140. | 2.1 | 46 |
| 230 | Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum. Nature Communications, 2021, 12, 5135. | 12.8 | 107 |
| 231 | Using Twitter for sentiment analysis towards AstraZeneca/Oxford, Pfizer/BioNTech and Moderna COVID-19 vaccines. Postgraduate Medical Journal, 2022, 98, 544-550. | 1.8 | 80 |
| 232 | Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan. Open Forum Infectious Diseases, 2021, 8, ofab430. | 0.9 | 18 |
| 233 | Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Medicine, 2021, 19, 208. | 5.5 | 52 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 234 | The New Variants of Corona-Virus Mutations: An Understanding to Their Infectivity, Immunological Tolerance and Vaccine Efficacy. Nano LIFE, 2021, 11, 2130010. | 0.9 | 1 |
| 235 | Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies. PLoS Pathogens, 2021, 17, e1009772. | 4.7 | 74 |
| 237 | A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. European Journal of Immunology, 2022, 52, 770-783. | 2.9 | 24 |
| 238 | The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum. EBioMedicine, 2021, 71, 103544. | 6.1 | 38 |
| 240 | Fast SARS-CoV-2 Variant Detection Using Snapback Primer High-Resolution Melting. Diagnostics, 2021, 11, 1788. | 2.6 | 8 |
| 241 | In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 111-117. | 5.7 | 69 |
| 242 | Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. Cell Reports Medicine, 2021, 2, 100405. | 6.5 | 110 |
| 243 | Genetic drift in the genome of SARS-CoV-2 and its global health concern. Journal of Medical Virology, 2022, 94, 88-98. | 5.0 | 17 |
| 244 | An ultrapotent pan- β -coronavirus lineage B (β -CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. Protein and Cell, 2022, 13, 655-675. | 11.0 | 25 |
| 245 | From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomaterialia, 2021, 131, 16-40. | 8.3 | 140 |
| 246 | Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. Cell Reports, 2021, 37, 109784. | 6.4 | 20 |
| 248 | Neglected roles of IgG Fc-binding protein secreted from airway mucin-producing cells in protecting against SARS-CoV-2 infection. Innate Immunity, 2021, 27, 423-436. | 2.4 | 6 |
| 249 | Cheap and Commonplace: Making the Case for BCG and $\gamma\delta$ T Cells in COVID-19. Frontiers in Immunology, 2021, 12, 743924. | 4.8 | 4 |
| 250 | Single base mutations in the nucleocapsid gene of SARS-CoV-2 affects amplification efficiency of sequence variants and may lead to assay failure. Journal of Clinical Virology Plus, 2021, 1, 100037. | 1.0 | 6 |
| 251 | Synthetic proteins for COVID-19 diagnostics. Peptides, 2021, 143, 170583. | 2.4 | 5 |
| 252 | Exploring the Interaction between E484K and N501Y Substitutions of SARS-CoV-2 in Shaping the Transmission Advantage of COVID-19 in Brazil: A Modeling Study. American Journal of Tropical Medicine and Hygiene, 2021, 105, 1247-1254. | 1.4 | 5 |
| 253 | Rapid and Quantitative Detection of Human Antibodies against the 2019 Novel Coronavirus SARS-CoV-2 and Its Variants as a Result of Vaccination and Infection. Microbiology Spectrum, 2021, 9, e0089021. | 3.0 | 2 |
| 254 | E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil. Infection, Genetics and Evolution, 2021, 93, 104941. | 2.3 | 58 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 255 | Understanding the molecular interaction of SARS-CoV-2 spike mutants with ACE2 (angiotensin) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 74 | 3.5 | 19 |
| 257 | Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. Vaccines, 2021, 9, 1052. | 4.4 | 22 |
| 258 | SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1. Vaccine, 2021, 39, 5769-5779. | 3.8 | 23 |
| 259 | The biological and clinical significance of emerging SARS-CoV-2 variants. Nature Reviews Genetics, 2021, 22, 757-773. | 16.3 | 778 |
| 260 | Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. Biomedicines, 2021, 9, 1303. | 3.2 | 87 |
| 261 | A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels. Scientific Reports, 2021, 11, 18428. | 3.3 | 10 |
| 262 | Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity. Briefings in Bioinformatics, 2022, 23, . | 6.5 | 16 |
| 263 | REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. New England Journal of Medicine, 2021, 385, e81. | 27.0 | 487 |
| 264 | Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. Cell, 2021, 184, 4969-4980.e15. | 28.9 | 94 |
| 265 | Comparison of an inactivated Covid19 vaccine-induced antibody response with concurrent natural Covid19 infection. International Journal of Infectious Diseases, 2021, 113, 58-64. | 3.3 | 24 |
| 266 | RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates. Cell Discovery, 2021, 7, 82. | 6.7 | 22 |
| 267 | Application of Artificial Intelligence in COVID-19 Diagnosis and Therapeutics. Journal of Personalized Medicine, 2021, 11, 886. | 2.5 | 17 |
| 268 | Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic. Infection, Genetics and Evolution, 2021, 93, 104971. | 2.3 | 19 |
| 269 | Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines. Frontiers in Immunology, 2021, 12, 708848. | 4.8 | 7 |
| 270 | mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity, 2021, 54, 2893-2907.e5. | 14.3 | 107 |
| 271 | COVID-19 vaccine uptake among healthcare workers in the fourth country to authorize BNT162b2 during the first month of rollout. Vaccine, 2021, 39, 5762-5768. | 3.8 | 49 |
| 272 | Emergence of the Delta Plus variant of SARS-CoV-2 in Iran. Gene Reports, 2021, 25, 101341. | 0.8 | 12 |
| 273 | Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies. Journal of Medical Virology, 2022, 94, 399-403. | 5.0 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 274 | Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. New England Journal of Medicine, 2021, 385, 1761-1773. | 27.0 | 1,090 |
| 275 | A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency. Antiviral Research, 2021, 194, 105147. | 4.1 | 11 |
| 276 | Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected. Journal of Infection, 2021, 83, 467-472. | 3.3 | 28 |
| 277 | Deamidation drives molecular aging of the SARS-CoV-2 spike protein receptor-binding motif. Journal of Biological Chemistry, 2021, 297, 101175. | 3.4 | 3 |
| 278 | Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2. Infection, Genetics and Evolution, 2021, 95, 105038. | 2.3 | 110 |
| 279 | Wastewater SARS-CoV-2 monitoring as a community-level COVID-19 trend tracker and variants in Ohio, United States. Science of the Total Environment, 2021, 801, 149757. | 8.0 | 107 |
| 280 | Highly sensitive and ultra-rapid antigen-based detection of SARS-CoV-2 using nanomechanical sensor platform. Biosensors and Bioelectronics, 2022, 195, 113647. | 10.1 | 34 |
| 281 | Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target. Immune Network, 2021, 21, e8. | 3.6 | 3 |
| 282 | Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy. Emerging Microbes and Infections, 2021, 10, 710-712. | 6.5 | 7 |
| 283 | Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination. Emerging Microbes and Infections, 2021, 10, 1390-1403. | 6.5 | 16 |
| 285 | Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection. Physical Chemistry Chemical Physics, 2021, 23, 22957-22971. | 2.8 | 11 |
| 286 | SARS-CoV-2 Variants of Concern. Yonsei Medical Journal, 2021, 62, 961. | 2.2 | 183 |
| 287 | A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies. International Journal of Immunopathology and Pharmacology, 2021, 35, 205873842110501. | 2.1 | 26 |
| 288 | INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants. Npj Vaccines, 2021, 6, 121. | 6.0 | 36 |
| 289 | Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera. IScience, 2021, 24, 103341. | 4.1 | 47 |
| 290 | Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore. Npj Vaccines, 2021, 6, 125. | 6.0 | 17 |
| 291 | Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clinical Microbiology and Infection, 2022, 28, 202-221. | 6.0 | 569 |
| 292 | Molecular Analysis and Genome Sequencing of SARS-Cov-2 during Second Wave 2021 Revealed Variant Diversity in India. Journal of Pure and Applied Microbiology, 0, , . | 0.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 293 | Vaccination against COVID-19 for hematologic patients: A review of clinical guidelines. <i>Gematologiya i Transfuziologiya</i> , 2021, 66, 458-470. | 0.6 | 1 |
| 294 | Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. <i>Nature</i> , 2021, 600, 523-529. | 27.8 | 194 |
| 295 | Imaging and visualizing SARS-CoV-2 in a new era for structural biology. <i>Interface Focus</i> , 2021, 11, 20210019. | 3.0 | 5 |
| 296 | Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks. <i>Vaccines</i> , 2021, 9, 1130. | 4.4 | 36 |
| 297 | ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. <i>Nature Communications</i> , 2021, 12, 5868. | 12.8 | 52 |
| 298 | Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro. <i>FASEB Journal</i> , 2021, 35, e21970. | 0.5 | 22 |
| 299 | Real-time quantification of the transmission advantage associated with a single mutation in pathogen genomes: a case study on the D614G substitution of SARS-CoV-2. <i>BMC Infectious Diseases</i> , 2021, 21, 1039. | 2.9 | 2 |
| 300 | COVID-19 Vaccine Platforms: Challenges and Safety Contemplations. <i>Vaccines</i> , 2021, 9, 1196. | 4.4 | 15 |
| 301 | A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. <i>Nature Communications</i> , 2021, 12, 6197. | 12.8 | 61 |
| 302 | Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy. <i>Advanced Materials</i> , 2021, 33, e2103471. | 21.0 | 60 |
| 303 | Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing. <i>Ageing Research Reviews</i> , 2022, 73, 101494. | 10.9 | 11 |
| 304 | Comparative characteristics of COVID-19 vaccines used for mass immunisation. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2021, 21, 158-166. | 0.5 | 6 |
| 305 | Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines. <i>Viruses</i> , 2021, 13, 2127. | 3.3 | 6 |
| 307 | GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. <i>Science Translational Medicine</i> , 2022, 14, eabj1996. | 12.4 | 18 |
| 308 | Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. <i>Cell Discovery</i> , 2021, 7, 96. | 6.7 | 21 |
| 311 | Mutational profile confers increased stability of SARS-CoV-2 spike protein in Brazilian isolates. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 13184-13189. | 3.5 | 3 |
| 312 | A practical approach to SARS-CoV-2 testing in a pre and post-vaccination era. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100044. | 1.0 | 2 |
| 313 | Complete protection by a single-dose skin patch-delivered SARS-CoV-2 spike vaccine. <i>Science Advances</i> , 2021, 7, eabj8065. | 10.3 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 314 | Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago. <i>Advanced Science</i> , 2022, 9, e2102181. | 11.2 | 14 |
| 315 | SARS-CoV-2 surveillance in Italy through phylogenomic inferences based on Hamming distances derived from pan-SNPs, -MNP and -InDels. <i>BMC Genomics</i> , 2021, 22, 782. | 2.8 | 12 |
| 316 | Survey of SARS-CoV-2 genetic diversity in two major Brazilian cities using a fast and affordable Sanger sequencing strategy. <i>Genomics</i> , 2021, 113, 4109-4115. | 2.9 | 9 |
| 317 | Immuno-informatics analysis predicts B and T cell consensus epitopes for designing peptide vaccine against SARS-CoV-2 with 99.82% global population coverage. <i>Briefings in Bioinformatics</i> , 2022, 23, . | 6.5 | 5 |
| 318 | Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine. <i>Frontiers in Immunology</i> , 2021, 12, 747830. | 4.8 | 69 |
| 319 | A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants. <i>Egyptian Journal of Bronchology</i> , 2021, 15, . | 0.8 | 4 |
| 320 | SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. <i>Epidemiology and Infection</i> , 2021, 149, 1-24. | 2.1 | 43 |
| 321 | Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern. <i>Clinical Infectious Diseases</i> , 2022, 74, 1899-1905. | 5.8 | 15 |
| 322 | SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response. <i>Emerging Microbes and Infections</i> , 2021, 10, 2235-2243. | 6.5 | 31 |
| 323 | Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China. <i>Innovation(China)</i> , 2022, 3, 100181. | 9.1 | 8 |
| 324 | Coronavirus Disease Update on Epidemiology, Virology, and Prevention. <i>Compendium of Continuing Education in Dentistry (Jamesburg, N J: 1995)</i> , 2021, 42, 280-289. | 0.1 | 0 |
| 325 | The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. <i>Vaccines</i> , 2021, 9, 1345. | 4.4 | 22 |
| 326 | National responses to covid-19: drivers, complexities, and uncertainties in the first year of the pandemic. <i>BMJ, The</i> , 2021, 375, e068954. | 6.0 | 11 |
| 327 | The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. <i>Nature</i> , 2022, 602, 294-299. | 27.8 | 364 |
| 328 | Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. <i>ELife</i> , 2021, 10, . | 6.0 | 63 |
| 329 | Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. <i>Scientific Reports</i> , 2021, 11, 22777. | 3.3 | 159 |
| 330 | Immune response against SARS-CoV-2 variants: the role of neutralization assays. <i>Npj Vaccines</i> , 2021, 6, 142. | 6.0 | 26 |
| 331 | Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies. <i>Npj Vaccines</i> , 2021, 6, 139. | 6.0 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 332 | Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. Biomedicines, 2021, 9, 1740. | 3.2 | 16 |
| 333 | Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. Journal of Virology, 2022, 96, JVI0155121. | 3.4 | 18 |
| 334 | Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. Seminars in Immunology, 2021, 55, 101533. | 5.6 | 72 |
| 335 | Phylogenetic and full-length genome mutation analysis of SARS-CoV-2 in Indonesia prior to COVID-19 vaccination program in 2021. Bulletin of the National Research Centre, 2021, 45, 200. | 1.8 | 8 |
| 337 | Antibody cocktail effective against variants of SARS-CoV-2. Journal of Biomedical Science, 2021, 28, 80. | 7.0 | 17 |
| 338 | Covid-19 vaccines and variants of concern: A review. Reviews in Medical Virology, 2022, 32, e2313. | 8.3 | 201 |
| 339 | Emerging Mutations Potentially Related to SARS-CoV-2 Immune Escape: The Case of a Long-Term Patient. Life, 2021, 11, 1259. | 2.4 | 2 |
| 340 | COVID-19 reinfection: the role of natural immunity, vaccines, and variants. Journal of Community Hospital Internal Medicine Perspectives, 2021, 11, 733-739. | 0.8 | 22 |
| 341 | CRISPR-Cas12a-Based Detection for the Major SARS-CoV-2 Variants of Concern. Microbiology Spectrum, 2021, 9, e0101721. | 3.0 | 40 |
| 342 | A year living with SARS-CoV-2: an epidemiological overview of viral lineage circulation by whole-genome sequencing in Barcelona city (Catalonia, Spain). Emerging Microbes and Infections, 2022, 11, 172-181. | 6.5 | 17 |
| 343 | A review of epidemiology and public health control measures of COVID-19 variants in Hong Kong, December 2020 to June 2021. IJID Regions, 2022, 2, 16-24. | 1.3 | 8 |
| 344 | Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. Scientific Reports, 2021, 11, 22848. | 3.3 | 57 |
| 345 | Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity. Microbiology Spectrum, 2021, 9, e0056121. | 3.0 | 15 |
| 346 | SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera. IScience, 2021, 24, 103467. | 4.1 | 26 |
| 347 | The intestinal microbiota and improving the efficacy of COVID-19 vaccinations. Journal of Functional Foods, 2021, 87, 104850. | 3.4 | 23 |
| 348 | Evolutionary Dynamics of Indels in SARS-CoV-2 Spike Glycoprotein. Evolutionary Bioinformatics, 2021, 17, 117693432110646. | 1.2 | 5 |
| 349 | OUP accepted manuscript. Clinical Chemistry, 2022, , . | 3.2 | 12 |
| 350 | Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants. Microbiology Spectrum, 2022, 10, e0150421. | 3.0 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 351 | Isolation and characterization of SARS-CoV-2 Beta variant from UAE travelers. <i>Journal of Infection and Public Health</i> , 2022, 15, 182-186. | 4.1 | 22 |
| 352 | Incidence Evaluation of SARS-CoV-2 Variants in the Ulsan Area, Korea, Using PowerChek SARS-CoV-2 S-gene Mutation Detection Kit: A Pilot Study. <i>Annals of Laboratory Medicine</i> , 2022, 42, 363-366. | 2.5 | 2 |
| 353 | SARS-CoV-2 mRNA Vaccine Breakthrough Infections in Fully Vaccinated Healthcare Personnel: A Systematic Review. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 9. | 2.3 | 14 |
| 354 | First Identification of the New Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant (B.1.1.529) in Italy. <i>Clinical Infectious Diseases</i> , 2022, 75, 522-524. | 5.8 | 17 |
| 355 | Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 816220. | 4.8 | 22 |
| 357 | Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1242-1252.e12. | 2.9 | 23 |
| 358 | Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339. | 16.0 | 9 |
| 360 | The ins and outs of SARS-CoV-2 variants of concern (VOCs). <i>Archives of Virology</i> , 2022, 167, 327-344. | 2.1 | 35 |
| 361 | SARS-CoV-2 Variants, Vaccines, and Host Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 809244. | 4.8 | 176 |
| 362 | SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 8-19. | 4.9 | 5 |
| 363 | Multiplexed Lab-on-a-Chip Bioassays for Testing Antibodies against SARS-CoV-2 and Its Variants in Multiple Individuals. <i>Analytical Chemistry</i> , 2022, 94, 2510-2516. | 6.5 | 7 |
| 364 | Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 72. | 4.4 | 13 |
| 365 | The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641. | 2.6 | 22 |
| 366 | Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants in vitro. <i>Frontiers in Pharmacology</i> , 2021, 12, 755600. | 3.5 | 34 |
| 369 | The Effectiveness of COVID-19 Vaccines in Improving the Outcomes of Hospitalized COVID-19 Patients. <i>Cureus</i> , 2022, 14, e21485. | 0.5 | 10 |
| 370 | Regional and temporal coordinated mutation patterns in SARS-CoV-2 spike protein revealed by a clustering and network analysis. <i>Scientific Reports</i> , 2022, 12, 1128. | 3.3 | 28 |
| 371 | Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort. <i>Vaccine</i> , 2022, 40, 811-818. | 3.8 | 9 |
| 372 | Distinct mutations and lineages of SARS-CoV-2 virus in the early phase of COVID-19 pandemic and subsequent 1-year global expansion. <i>Journal of Medical Virology</i> , 2022, 94, 2035-2049. | 5.0 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 373 | In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant. <i>Transboundary and Emerging Diseases</i> , 2022, 69, 2649-2655. | 3.0 | 1 |
| 374 | Immune dynamics of SARS-CoV-2 virus evolution. <i>International Journal of Molecular and Immunology</i> , 0, 7, 3-15. | 0.0 | 2 |
| 375 | Limited spread of a rare spike E484K-harboring SARS-CoV-2 in Marseille, France. <i>Archives of Virology</i> , 2022, 167, 583. | 2.1 | 3 |
| 376 | COVID-19 reinfections among naturally infected and vaccinated individuals. <i>Scientific Reports</i> , 2022, 12, 1438. | 3.3 | 79 |
| 378 | Analisis Efikasi dan Efektivitas Vaksin COVID-19 terhadap Varian SARS-CoV-2: Sebuah Tinjauan Literatur. <i>Jurnal Kedokteran Meditek</i> , 2022, 28, 107-119. | 0.0 | 0 |
| 379 | Strategies for fighting pandemic virus infections: Integration of virology and drug delivery. <i>Journal of Controlled Release</i> , 2022, 343, 361-378. | 9.9 | 11 |
| 380 | Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity. <i>Journal of Infection and Public Health</i> , 2022, 15, 277-288. | 4.1 | 21 |
| 381 | Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein. <i>Virus Research</i> , 2022, 310, 198674. | 2.2 | 24 |
| 382 | Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria. <i>Nature Communications</i> , 2022, 13, 688. | 12.8 | 23 |
| 383 | Characterization of Two Heterogeneous Lethal Mouse-Adapted SARS-CoV-2 Variants Recapitulating Representative Aspects of Human COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 821664. | 4.8 | 22 |
| 384 | Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. <i>Nature Communications</i> , 2022, 13, 852. | 12.8 | 92 |
| 385 | A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12. | 3.3 | 94 |
| 386 | SARS-CoV-2 Variants and Vaccination. <i>Zoonoses</i> , 2022, 2, . | 1.1 | 16 |
| 387 | Analysis of COVID-19 Risk Following a Ring Vaccination Intervention to Address SARS-CoV-2 Alpha Variant Transmission in Montreal, Canada. <i>JAMA Network Open</i> , 2022, 5, e2147042. | 5.9 | 2 |
| 388 | A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. <i>PLoS Pathogens</i> , 2022, 18, e1010248. | 4.7 | 48 |
| 389 | Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera. <i>Viruses</i> , 2022, 14, 335. | 3.3 | 12 |
| 390 | Rapid characterization of spike variants via mammalian cell surface display. <i>Molecular Cell</i> , 2021, 81, 5099-5111.e8. | 9.7 | 32 |
| 391 | A rapid and affordable point of care test for antibodies against SARS-CoV-2 based on hemagglutination and artificial intelligence interpretation. <i>Scientific Reports</i> , 2021, 11, 24507. | 3.3 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 392 | Deep dissection of the antiviral immune profile of patients with COVID-19. Communications Biology, 2021, 4, 1389. | 4.4 | 9 |
| 393 | SARS-CoV-2 spreads through cell-to-cell transmission. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, . | 7.1 | 145 |
| 396 | Omicron SARS-CoV-2 Variant Spike Protein Shows an Increased Affinity to the Human ACE2 Receptor: An In Silico Analysis. Pathogens, 2022, 11, 45. | 2.8 | 44 |
| 397 | Hyperglycosylated spike of SARS-CoV-2 gamma variant induces breast cancer metastasis. American Journal of Cancer Research, 2021, 11, 4994-5005. | 1.4 | 0 |
| 398 | Clinical characteristics of COVID-19 patients in Xiaogan, China: comparison between recent imported cases and earlier local cases. American Journal of Translational Research (discontinued), 2021, 13, 11999-12005. | 0.0 | 0 |
| 399 | Vaccine efficacy in mutant SARS-CoV-2 variants. , 2021, 4, 1-12. | | 4 |
| 400 | Microfluidic point-of-care device for detection of early strains and B.1.1.7 variant of SARS-CoV-2 virus. Lab on A Chip, 2022, 22, 1297-1309. | 6.0 | 25 |
| 401 | Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination. Theranostics, 2022, 12, 2519-2534. | 10.0 | 3 |
| 403 | The guiding principles for populational COVID-19 vaccine selection: A normative analysis through comparison of the strategies in Hong Kong and Singapore. Journal of Global Health, 2022, 12, 03004. | 2.7 | 2 |
| 406 | SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. Pathogens, 2022, 11, 275. | 2.8 | 9 |
| 407 | mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. Scientific Reports, 2022, 12, 2628. | 3.3 | 34 |
| 408 | Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. Cell Host and Microbe, 2022, 30, 485-488.e3. | 11.0 | 80 |
| 410 | Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern. Signal Transduction and Targeted Therapy, 2022, 7, 61. | 17.1 | 12 |
| 412 | SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. Frontiers in Medicine, 2022, 9, 815389. | 2.6 | 96 |
| 413 | Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. Medical Microbiology and Immunology, 2022, 211, 79-103. | 4.8 | 9 |
| 414 | Structural Dynamics and Molecular Evolution of the SARS-CoV-2 Spike Protein. MBio, 2022, 13, e0203021. | 4.1 | 10 |
| 416 | Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants. Frontiers in Immunology, 2022, 13, 861050. | 4.8 | 8 |
| 417 | Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 2022, 605, 640-652. | 27.8 | 117 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 419 | Natural SARS-CoV-2 Infection Affects Neutralizing Activity in Saliva of Vaccinees. <i>Frontiers in Immunology</i> , 2022, 13, 820250. | 4.8 | 20 |
| 420 | The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921. | 4.1 | 117 |
| 421 | Mutations in the genome of severe acute respiratory syndrome coronavirus 2: implications for COVID-19 severity and progression. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210864. | 1.0 | 5 |
| 422 | Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies. <i>Frontiers in Immunology</i> , 2022, 13, 797589. | 4.8 | 30 |
| 423 | A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines. <i>AAPS PharmSciTech</i> , 2022, 23, 95. | 3.3 | 3 |
| 424 | Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents. <i>Scientific Reports</i> , 2022, 12, 3788. | 3.3 | 22 |
| 425 | Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds. <i>Frontiers in Immunology</i> , 2022, 13, 773982. | 4.8 | 10 |
| 426 | The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. <i>EBioMedicine</i> , 2022, 77, 103902. | 6.1 | 23 |
| 427 | Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm. <i>Journal of Personalized Medicine</i> , 2022, 12, 386. | 2.5 | 5 |
| 428 | Spike protein of SARS-CoV-2 variants: a brief review and practical implications. <i>Brazilian Journal of Microbiology</i> , 2022, 53, 1133-1157. | 2.0 | 22 |
| 429 | David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors. <i>MAbs</i> , 2022, 14, 2057832. | 5.2 | 7 |
| 430 | BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, 41. | 6.0 | 4 |
| 431 | The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape. <i>International Journal of Biological Macromolecules</i> , 2022, 208, 105-125. | 7.5 | 41 |
| 432 | Experimental veterinary SARS-CoV-2 vaccine cross neutralization of the Delta (B.1.617.2) variant virus in cats. <i>Veterinary Microbiology</i> , 2022, 268, 109395. | 1.9 | 6 |
| 433 | The non-pharmaceutical interventions may affect the advantage in transmission of mutated variants during epidemics: A conceptual model for COVID-19. <i>Journal of Theoretical Biology</i> , 2022, 542, 111105. | 1.7 | 5 |
| 435 | Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays. <i>Viruses</i> , 2022, 14, 69. | 3.3 | 5 |
| 436 | Development of an efficient Sanger sequencing-based assay for detecting SARS-CoV-2 spike mutations. <i>PLoS ONE</i> , 2021, 16, e0260850. | 2.5 | 11 |
| 437 | Analysis of Clinical Characteristics and Virus Strains Variation of Patients Infected With SARS-CoV-2 in Jiangsu Province—A Retrospective Study. <i>Frontiers in Public Health</i> , 2021, 9, 791600. | 2.7 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 438 | Semi-Supervised Pipeline for Autonomous Annotation of SARS-CoV-2 Genomes. <i>Viruses</i> , 2021, 13, 2426. | 3.3 | 5 |
| 439 | Mutational landscape of SARS-CoV-2 genome in Turkey and impact of mutations on spike protein structure. <i>PLoS ONE</i> , 2021, 16, e0260438. | 2.5 | 6 |
| 440 | COVID-19 Vaccination: The Mainspring of Challenges and the Seed of Remonstrance. <i>Vaccines</i> , 2021, 9, 1474. | 4.4 | 6 |
| 441 | Advances in the design and development of SARS-CoV-2 vaccines. <i>Military Medical Research</i> , 2021, 8, 67. | 3.4 | 26 |
| 442 | Neutralization of SARS-CoV-2 Variants of Concern in Kidney Transplant Recipients after Standard COVID-19 Vaccination. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 98-106. | 4.5 | 22 |
| 443 | Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals. , 2022, 19, 588-601. | | 27 |
| 446 | Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains. <i>Viruses</i> , 2022, 14, 827. | 3.3 | 14 |
| 447 | Identification of Compounds With Antiviral Activity Against SARS-CoV-2 in the MMV Pathogen Box Using a Phenotypic High-Throughput Screening Assay. <i>Frontiers in Virology</i> , 2022, 2, . | 1.4 | 6 |
| 448 | Development of antibody resistance in emerging mutant strains of SARS CoVâ€2: Impediment for COVIDâ€19 vaccines. <i>Reviews in Medical Virology</i> , 2022, 32, e2346. | 8.3 | 16 |
| 449 | Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity. <i>Viruses</i> , 2022, 14, 803. | 3.3 | 10 |
| 450 | Omicron-included mutation-induced changes in epitopes of SARS-CoV-2 spike protein and effectiveness assessments of current antibodies. <i>Molecular Biomedicine</i> , 2022, 3, 12. | 4.4 | 12 |
| 451 | Risk factors for prolonged nucleic acid conversion time in patients with COVID-19.. <i>International Journal of Health Sciences</i> , 2022, 16, 32-36. | 0.4 | 0 |
| 454 | Pilot Investigation of SARS-CoV-2 Variants in the Island of Sicily Prior to and in the Second Wave of the COVID-19 Pandemic. <i>Frontiers in Microbiology</i> , 2022, 13, 869559. | 3.5 | 2 |
| 455 | SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance. <i>Frontiers in Immunology</i> , 2022, 13, 877101. | 4.8 | 74 |
| 456 | LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 39, 110812. | 6.4 | 287 |
| 457 | Peptide-Based Strategies Against SARS-CoV-2 Attack: An Updated In Silico Perspective. <i>Frontiers in Drug Discovery</i> , 2022, 2, . | 2.8 | 6 |
| 458 | Effect of cannabidiol on apoptosis and cellular interferon and interferon-stimulated gene responses to the SARS-CoV-2 genes ORF8, ORF10 and M protein. <i>Life Sciences</i> , 2022, 301, 120624. | 4.3 | 7 |
| 459 | COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants. <i>Cureus</i> , 2022, , . | 0.5 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 460 | Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host. <i>Nature Communications</i> , 2022, 13, 2560. | 12.8 | 64 |
| 461 | COVID-19 vaccine development: milestones, lessons and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 146. | 17.1 | 153 |
| 462 | nSARS-CoV-2 and COVID-19 Pandemic: From Emergence to Vaccination. <i>Dr Sulaiman Al Habib Medical Journal</i> , 0, , 1. | 0.8 | 0 |
| 463 | Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. <i>Nature</i> , 2022, 607, 119-127. | 27.8 | 174 |
| 464 | Bioinformatics for the Origin and Evolution of Viruses. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1368, 53-71. | 1.6 | 2 |
| 465 | Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines. <i>Indian Journal of Medical Research</i> , 2022, 155, 105. | 1.0 | 2 |
| 466 | Safety & effectiveness of COVID-19 vaccines: A narrative review. <i>Indian Journal of Medical Research</i> , 2022, 155, 91. | 1.0 | 22 |
| 467 | The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Concern. <i>Frontiers in Medicine</i> , 2022, 9, . | 2.6 | 43 |
| 468 | A conserved subunit vaccine designed against SARS-CoV-2 variants showed evidence in neutralizing the virus. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 4091-4114. | 3.6 | 6 |
| 469 | Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 1207-1221. | 2.6 | 3 |
| 470 | Real-World Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 0, 9, . | 2.6 | 25 |
| 471 | Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines. <i>Vaccine</i> , 2022, 40, 4017-4025. | 3.8 | 7 |
| 472 | Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization. <i>Microbiology Spectrum</i> , 2022, 10, . | 3.0 | 24 |
| 474 | Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants. <i>Viruses</i> , 2022, 14, 1332. | 3.3 | 12 |
| 475 | Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919. | 4.4 | 23 |
| 476 | IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers. <i>Frontiers in Immunology</i> , 0, 13, . | 4.8 | 16 |
| 477 | Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. <i>Nature Communications</i> , 2022, 13, . | 12.8 | 63 |
| 478 | mRNA delivery technologies: Toward clinical translation. <i>International Review of Cell and Molecular Biology</i> , 2022, , 207-293. | 3.2 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 479 | Severe acute respiratory syndrome coronavirus-2: An era of struggle and discovery leading to the emergency use authorization of treatment and prevention measures based on computational analysis. , 2022, , 559-582. | | 0 |
| 481 | Identification of SARS-CoV-2 Variants of Concern Using Amplicon Next-Generation Sequencing. Microbiology Spectrum, 2022, 10, . | 3.0 | 10 |
| 482 | mRNA vaccines: Past, present, future. Asian Journal of Pharmaceutical Sciences, 2022, 17, 491-522. | 9.1 | 24 |
| 483 | A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. Pharmaceutical Research, 2022, 39, 2119-2134. | 3.5 | 10 |
| 484 | Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection. Emerging Microbes and Infections, 2022, 11, 1828-1832. | 6.5 | 32 |
| 485 | Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera. Nature Communications, 2022, 13, . | 12.8 | 19 |
| 486 | Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. Journal of Experimental Medicine, 2022, 219, . | 8.5 | 6 |
| 487 | Clinical Performance of Rapid and Point-of-Care Antigen Tests for SARS-CoV-2 Variants of Concern: A Living Systematic Review and Meta-Analysis. Viruses, 2022, 14, 1479. | 3.3 | 13 |
| 488 | A novel hamster model of SARS-CoV-2 respiratory infection using a pseudotyped virus. Scientific Reports, 2022, 12, . | 3.3 | 1 |
| 489 | Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD. International Journal of Molecular Sciences, 2022, 23, 8177. | 4.1 | 5 |
| 490 | SARS-CoV-2â€™s Variants of Concern: A Brief Characterization. Frontiers in Immunology, 0, 13, . | 4.8 | 31 |
| 491 | Peimine inhibits variants of <scp>SARSâ€™CoV</scp> â€” cell entry via blocking the interaction between viral spike protein and <scp>ACE2</scp>. Journal of Food Biochemistry, 2022, 46, . | 2.9 | 8 |
| 492 | Dynamics of Viral Infection and Evolution of SARS-CoV-2 Variants in the Calabria Area of Southern Italy. Frontiers in Microbiology, 0, 13, . | 3.5 | 10 |
| 493 | Tracking the turnover of SARS-CoV-2 VOCs Gamma to Delta in a Brazilian state (Minas Gerais) with a high-vaccination status. Virus Evolution, 2022, 8, . | 4.9 | 10 |
| 494 | Understanding the Excitation Wavelength Dependence and Thermal Stability of the SARS-CoV-2 Receptor-Binding Domain Using Surface-Enhanced Raman Scattering and Machine Learning. ACS Photonics, 2022, 9, 2963-2972. | 6.6 | 10 |
| 495 | Missense mutations in spike protein of SARSâ€™CoVâ€™ delta variant contribute to the alteration in viral structure and interaction with hACE2 receptor. Immunity, Inflammation and Disease, 2022, 10, . | 2.7 | 6 |
| 496 | COVID-19 and vaccination: myths vs science. Expert Review of Vaccines, 2022, 21, 1603-1620. | 4.4 | 23 |
| 497 | Molecular dynamics and docking studies on potentially active natural phytochemicals for targeting SARS-CoV-2 main protease. Journal of Biomolecular Structure and Dynamics, 2023, 41, 6459-6475. | 3.5 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 498 | Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort. <i>Viruses</i> , 2022, 14, 1766. | 3.3 | 13 |
| 499 | Severity of Illness Caused by Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern in Children: A Single-Center Retrospective Cohort Study. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 440-447. | 1.3 | 15 |
| 500 | STANDARD M10 SARS-CoV-2 Assay for Rapid Detection of SARS-CoV-2: Comparison of Four Real-Time PCR Assays. <i>Diagnostics</i> , 2022, 12, 1998. | 2.6 | 4 |
| 501 | Comparison of SARS-CoV-2 spike RNA sequences in feces and nasopharynx indicates intestinal replication. <i>Gut Pathogens</i> , 2022, 14, . | 3.4 | 4 |
| 502 | Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants. <i>Journal of Clinical Immunology</i> , 2023, 43, 31-45. | 3.8 | 4 |
| 503 | Neutralization activity of sera/IgG preparations from fully BNT162b2 vaccinated individuals against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Kappa variants. <i>Scientific Reports</i> , 2022, 12, . | 3.3 | 9 |
| 504 | ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants. <i>Nature Communications</i> , 2022, 13, . | 12.8 | 23 |
| 505 | Fatality assessment and variant risk monitoring for COVID-19 using three new hospital occupancy related metrics. <i>EBioMedicine</i> , 2022, 83, 104225. | 6.1 | 2 |
| 506 | Unique mutations in SARS-CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion. <i>Microbial Pathogenesis</i> , 2022, 170, 105699. | 2.9 | 37 |
| 507 | SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies. , 2022, , 143-160. | | 0 |
| 508 | Knowledge of SARS-CoV-2 Epitopes and Population HLA Types Is Important in the Design of COVID-19 Vaccines. <i>Vaccines</i> , 2022, 10, 1606. | 4.4 | 4 |
| 509 | A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxisâ€”ICE-COVID. <i>Trials</i> , 2022, 23, . | 1.6 | 4 |
| 510 | Frontline workers: Mediators of mucosal immunity in community acquired pneumonia and COVID-19. <i>Frontiers in Immunology</i> , 0, 13, . | 4.8 | 0 |
| 511 | SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19. <i>Vaccines</i> , 2022, 10, 1538. | 4.4 | 12 |
| 512 | Quantifying Mutational Response to Track the Evolution of SARS-CoV-2 Spike Variants: Introducing a Statistical-Mechanics-Guided Machine Learning Method. <i>Journal of Physical Chemistry B</i> , 2022, 126, 7895-7905. | 2.6 | 5 |
| 513 | Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. <i>Science Translational Medicine</i> , 2022, 14, . | 12.4 | 55 |
| 514 | Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine. <i>Viruses</i> , 2022, 14, 2023. | 3.3 | 8 |
| 515 | Key mutations on spike protein altering ACE2 receptor utilization and potentially expanding host range of emerging SARSâ€CoVâ€2 variants. <i>Journal of Medical Virology</i> , 2023, 95, . | 5.0 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 516 | Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals. Scientific Reports, 2022, 12, . | 3.3 | 8 |
| 517 | Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions. Biomedicine and Pharmacotherapy, 2023, 157, 113977. | 5.6 | 66 |
| 518 | Molecular dynamics simulations of the spike trimeric ectodomain of the SARS-CoV-2 Omicron variant: structural relationships with infectivity, evasion to immune system and transmissibility. Journal of Biomolecular Structure and Dynamics, 2023, 41, 9326-9343. | 3.5 | 4 |
| 519 | ViMRT: a text-mining tool and search engine for automated virus mutation recognition. Bioinformatics, 2023, 39, . | 4.1 | 3 |
| 521 | The Role of Host Cell Glycans on Virus Infectivity: The SARS-CoV-2 Case. Advanced Science, 2023, 10, . | 11.2 | 4 |
| 522 | Genomic analysis of SARS-CoV-2 variants of concern circulating in Hawaiï™ to facilitate public-health policies. PLoS ONE, 2022, 17, e0278287. | 2.5 | 0 |
| 523 | Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. Nature Communications, 2022, 13, . | 12.8 | 17 |
| 524 | A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. Cell Reports, 2023, 42, 111903. | 6.4 | 34 |
| 525 | The Levels of Anti-SARS-CoV-2 Spike Protein IgG Antibodies Before and After the Third Dose of Vaccination Against COVID-19. Journal of Inflammation Research, 0, Volume 16, 145-160. | 3.5 | 5 |
| 526 | Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients. Heliyon, 2023, 9, e12704. | 3.2 | 2 |
| 527 | Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity. Medical Microbiology and Immunology, 2023, 212, 103-122. | 4.8 | 18 |
| 528 | Universal access to vaccines in post-COVID bioeconomy: Redesign for variants of concern and patent protection. , 2023, , 37-76. | | 0 |
| 529 | Tracking of Mutational Signature of SARS-CoV-2 Omicron on Distinct Continents and Little Difference was Found. Viruses, 2023, 15, 321. | 3.3 | 0 |
| 530 | Uptake of severe acute respiratory syndrome coronavirus 2 spike protein mediated by angiotensin converting enzyme 2 and ganglioside in human cerebrovascular cells. Frontiers in Neuroscience, 0, 17, . | 2.8 | 2 |
| 531 | Virus-like Particles of Nodavirus Displaying the Receptor Binding Domain of SARS-CoV-2 Spike Protein: A Potential VLP-Based COVID-19 Vaccine. International Journal of Molecular Sciences, 2023, 24, 4398. | 4.1 | 0 |
| 532 | Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. Nature Methods, 2023, 20, 512-522. | 19.0 | 111 |
| 533 | An update on SARS-CoV-2 immunization and future directions. Frontiers in Pharmacology, 0, 14, . | 3.5 | 2 |
| 534 | Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. Medicinal Research Reviews, 2023, 43, 932-971. | 10.5 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 535 | Identifying promising druggable binding sites and their flexibility to target the receptor-binding domain of SARS-CoV-2 spike protein. Computational and Structural Biotechnology Journal, 2023, 21, 2339-2351. | 4.1 | 5 |
| 536 | Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis. Viruses, 2023, 15, 856. | 3.3 | 10 |
| 537 | Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination. Cell Reports, 2023, 42, 112326. | 6.4 | 13 |
| 538 | Comprehensive deep mutational scanning reveals the pH induced stability and binding differences between SARS-CoV-2 spike RBD and human ACE2. Journal of Biomolecular Structure and Dynamics, 2023, 41, 15207-15218. | 3.5 | 1 |
| 539 | SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. , 2024, , 24-51. | | 0 |
| 540 | Lectin Fingerprinting Distinguishes Antibody Neutralization in SARS-CoV-2. ACS Central Science, 2023, 9, 947-956. | 11.3 | 1 |
| 541 | An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants. Nature Communications, 2023, 14, . | 12.8 | 7 |
| 542 | The high mutation rate at the D614G hotspot-furin cleavage site region increases the priming efficiency of the Spike protein by furin protease: analysis of Indonesian SARS-CoV-2 G614 variants obtained during the early COVID-19 pandemic. VirusDisease, 0, , . | 2.0 | 1 |
| 543 | A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo. Communications Biology, 2023, 6, . | 4.4 | 0 |
| 544 | Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity. Heliyon, 2023, 9, e16750. | 3.2 | 1 |
| 545 | Phylodynamic of SARS-CoV-2 during the second wave of COVID-19 in Peru. Nature Communications, 2023, 14, . | 12.8 | 3 |
| 546 | An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant. , 2023, 1, . | | 1 |
| 547 | How helpful were molecular dynamics simulations in shaping our understanding of SARS-CoV-2 spike protein dynamics?. International Journal of Biological Macromolecules, 2023, 242, 125153. | 7.5 | 3 |
| 548 | The Environmental Impacts of Natural Resources Depletion. Lecture Notes in Civil Engineering, 2023, , 705-714. | 0.4 | 0 |
| 550 | Antigenic evolution of SARS coronavirus 2. Current Opinion in Virology, 2023, 62, 101349. | 5.4 | 12 |
| 551 | Does environmental policy stringency influence CO2 emissions in the Asia Pacific region? A nonlinear perspective. Air Quality, Atmosphere and Health, 2023, 16, 2499-2508. | 3.3 | 8 |
| 552 | Characterization of a mouse-adapted strain of bat severe acute respiratory syndrome-related coronavirus. Journal of Virology, 2023, 97, . | 3.4 | 2 |
| 553 | Detection of SARS-CoV-2 426 ORF8 Deletion Mutant Cluster in NGS Screening. Microorganisms, 2023, 11, 2378. | 3.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 555 | Overview of immunological & virological factors driving the evolution & global spread of SARS-CoV-2 variants. Indian Journal of Medical Research, 2023, 158, 257. | 1.0 | 1 |
| 556 | Structure, dynamics and free energy studies on the effect of point mutations on SARS-CoV-2 spike protein binding with ACE2 receptor. PLoS ONE, 2023, 18, e0289432. | 2.5 | 1 |
| 558 | COV2Var, a function annotation database of SARS-CoV-2 genetic variation. Nucleic Acids Research, 2024, 52, D701-D713. | 14.5 | 2 |
| 559 | Unveiling asymmetric dynamics: Exploring the impact of oil price on economic growth and current account deficit: Evidence from G-7 countries. Resources Policy, 2024, 89, 104481. | 9.6 | 0 |
| 560 | Molecular Dynamics Simulations on Spike Protein Mutants Binding with Human β 2 Defensin Type 2. Journal of Physical Chemistry B, 2024, 128, 415-428. | 2.6 | 0 |
| 562 | A proposed analytical approach to estimate excess daily mortality rates in Ecuador. Frontiers in Public Health, 0, 12, . | 2.7 | 0 |